Achromobacter Xylosoxidans Bacteremia: A Retrospective Review Between 2015-2022 of 77 Published Cases Describing the Demographics, Clinical Features, Risk Factors and Outcomes
Journal of Infectious Diseases & Travel Medicine · 04.09.2026 · 10 (2) · 1-7
DOI: 10.23880/jidtm-16000207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Infectious Diseases & Travel Medicine, online erschienen am 04.09.2026. Verfasst von Antony S.
Abstract (Originalsprache)
Background
Achromobacter xylosoxidans is an opportunistic, aerobic, gram-negative, non-fermenting bacillus increasingly recognized as a healthcare-associated pathogen, particularly in immunocompromised and critically ill patients. Intrinsic and acquired resistance to multiple antimicrobial agents makes bloodstream infection with this organism difficult to treat.
Methods
We conducted a structured retrospective review of 77 published cases of A. xylosoxidans bacteremia from case reports and case series between 2007 and 2025 and included one institutional case within that series. Data on demographics, comorbidities, infection sources, antimicrobial susceptibilities, and outcomes were extracted and analyzed using descriptive statistics.
Results
Mean age was 43.6 years (range, neonate to 86 years); 41 of 77 patients (53.2%) were male. Common comorbidities were hematologic malignancy (25/77, 32.5%), cystic fibrosis (12/77, 15.6%), and diabetes with end-stage renal disease (10/77, 13.0%). Central venous catheters were the most common source (30/77, 39.0%). Device-associated infection accounted for 48 of 77 cases (62.3%). Meropenem, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole had the highest reported susceptibility rates (88%, 79%, and 75%, respectively). Endovascular infection (22/77, 28.6%) was associated with higher morbidity (>75% ICU-level care or prolonged hospitalization) and mortality (5/22, 22.7%) than non-endovascular infection (9/55, 16.4%). Septic shock occurred in 12 patients, with 6 deaths (50%). Overall mortality was 14 of 77 (18.2%).
Conclusion
A. xylosoxidans bacteremia predominantly affects immunocompromised patients and carries substantial morbidity and mortality. Most cases were associated with indwelling vascular devices. Meropenem, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole demonstrated the highest reported in vitro susceptibility in this series. Early identification, source control, and timely administration of effective antimicrobial therapy are essential.
Zitieren
APA
S, A. (2026). Achromobacter Xylosoxidans Bacteremia: A Retrospective Review Between 2015-2022 of 77 Published Cases Describing the Demographics, Clinical Features, Risk Factors and Outcomes. Journal of Infectious Diseases & Travel Medicine, 10(2), 1-7. https://doi.org/10.23880/jidtm-16000207
Vancouver
S A. Achromobacter Xylosoxidans Bacteremia: A Retrospective Review Between 2015-2022 of 77 Published Cases Describing the Demographics, Clinical Features, Risk Factors and Outcomes. Journal of Infectious Diseases & Travel Medicine. 2026;10(2):1-7. doi:10.23880/jidtm-16000207
BibTeX
@article{S2026,
author = {S, Antony},
title = {Achromobacter Xylosoxidans Bacteremia: A Retrospective Review Between 2015-2022 of 77 Published Cases Describing the Demographics, Clinical Features, Risk Factors and Outcomes},
journal = {Journal of Infectious Diseases & Travel Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {1--7},
doi = {10.23880/jidtm-16000207}
}
EUVIMED